#mmsm
LightNews LightNews
chandlerrome.bsky.social
New Crush City Territory episode

- First impressions of Randy Flores
- Jim Crane's comments
- More

YouTube: www.youtube.com/watch?v=mmsM...

Apple: podcasts.apple.com/us/podcast/c...

Spotify: open.spotify.com/episode/6z4X...
The Flores Files: First Impressions of the Astros’ New GM | Crush City Territory
YouTube video by Crush City Territory: A Houston Astros Show
www.youtube.com
November 3, 2026 at 4:53 PM
ash.hematology.org
CMS has expanded Medicare coverage for autologous stem cell transplants for patients with multiple myeloma!

ASH applauds this decision, which follows collaborative advocacy efforts to improve access to care.

Read more: https://ow.ly/cJvr5102r9l

#Hematology #MMsm
October 30, 2026 at 5:54 PM
onclive.bsky.social
Ongoing research and evolving prophylactic measures are helping integrate bispecific antibodies further into community practice for the management of relapsed/refractory multiple myeloma #mmsm #oncology

Read more: www.onclive.com/view/outpati...
Outpatient Models and Prophylactic Measures Help Bring Bispecifics Into Community Practice for R/R Myeloma | OncLive
Faculty at an OncLive Scientific Interchange and Workshop discussed operationalizing outpatient bispecific antibody therapy for relapsed/refractory multiple myeloma.
www.onclive.com
November 3, 2026 at 4:00 PM
imfmyeloma.bsky.social
Who is this new CELMoD for? Learn more about Zenbexus, the first CELMoD approved for multiple myeloma treatment.

#AsktheIMF #mmsm
October 26, 2026 at 8:08 PM
ashclinicalnews.bsky.social
Combining the bispecific antibody teclistamab with daratumumab and lenalidomide resulted in deep responses among patients with newly diagnosed #MMsm who were eligible for stem cell transplant, with an MRD-negative CR of 91.8% and a 100% ORR at six months: https://ow.ly/wcXS5100I5b
October 27, 2026 at 3:00 PM
onclive.bsky.social
Topline data from the phase 3 MagnetisMM-32 trial showed elranatamab improved PFS vs SOC in R/R multiple myeloma treated with at least 1 prior line of therapy that included an anti-CD38 monoclonal antibody and lenalidomide #mmsm #oncology

Read more: www.onclive.com/view/elranat...
October 27, 2026 at 2:26 PM
onclive.bsky.social
Just in: Teclistamab monotherapy is now approved in the EU for relapsed/refractory multiple myeloma following at least 1 prior line of therapy #mmsm #oncology

Read more: www.onclive.com/view/teclist...
October 23, 2026 at 3:45 PM
airplane-pictures.net
#Douglas #C-47A Skytrain, #Mexico - Air Force (6042) by Guillermo Quiroz Martínez (#Santa Lucia AB) #Military #aviation #photography #avgeeks
Mexico - Air Force Douglas C-47A Skytrain 6042 at Santa Lucia AB MMSM (Photo by Guillermo Quiroz Martínez)
Photo of 6042 Douglas C-47A Skytrain of Mexico - Air Force at MMSM Santa Lucia AB - Mexico © Guillermo Quiroz Martínez 1986
airplane-pictures.net
October 19, 2026 at 7:53 PM
onclive.bsky.social
Following the June 2026 approval of subcutaneous isatuximab by Japan's Ministry of Health, Labour and Welfare, the regulatory agency has also approved the CirCLIQ injector for on-body administration of the anti-CD38 antibody in multiple myeloma #mmsm #oncology www.onclive.com/view/japan-a...
Japan Approves On-Body Injector for Subcutaneous Isatuximab in Multiple Myeloma | OncLive
The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
www.onclive.com
October 19, 2026 at 4:14 PM
celebplanes.bsky.social
Wheels down for Sergio Perez at MMSM. 4h 45m on XA-ASP, the Bombardier Challenger 604. FL381 cruise · ~1,188 gal.
#celebplanes #celebjettracking #privatejet #avgeek #sergioperez #bombardierchallenger604
celebplanes.com/flight/26312
Sergio Perez · CYQB → MMSM · 4h 45m. Hero card with photo and route. Sergio Perez · CYQB → MMSM · 4h 45m. Aircraft photo, flight path map, and flight stats.
October 13, 2026 at 9:08 PM
imfmyeloma.bsky.social
Is multiple myeloma hereditary, environmental, or both? IMF Nurse Leadership Board member Beth Faiman explains in this short clip.

#AsktheIMF #mmsm
October 13, 2026 at 2:01 PM
suadeukae.fairy.blue
tá joia, chuchu, brigadinho assim mmsm ^_^
October 12, 2026 at 7:09 PM
eshaematology.bsky.social
📣 PRESENTING THE MAIN TOPICS OF #ESHCART2027
4th How I Manage CAR-T Therapies & Bispecific Antibodies for my Patients
Sept. 24-26, 2027|Stockholm, Sweden
Chairs: Michael Hudecek, Caron Jacobson, Marie José Kersten
For more information ➡ bit.ly/4ckiDZT
#ESHCONFERENCES #HAEMATOLOGY #MMsm #Lmsm
October 14, 2026 at 8:46 AM
onclive.bsky.social
CAR T or bispecifics at early relapse? Omar Castaneda Puglianini, MD, of @moffittnews.bsky.social, breaks down considerations for treatment selection/sequencing as T-cell–redirecting therapies continue to move earlier in the myeloma treatment paradigm #mmsm #oncology www.onclive.com/view/earlier...
Earlier CAR T-Cell Therapy Use Highlights Sequencing and Access Considerations in Myeloma | OncLive
Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.
www.onclive.com
October 13, 2026 at 1:07 PM
eshaematology.bsky.social
📣 #ESHLYMPHOMA2026 PROGRAMME HIGHLIGHT:
ROUNDTABLE 1 “TOX and PRO”
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #Haematology #MMsm #Lmsm
October 13, 2026 at 7:40 AM
onclive.bsky.social
Last week’s #OncFive:
✅ Atezolizumab approved for CRC #crcsm #oncology
🎗️ Tucatinib approved for breast cancer #bcsm
🩸 IberDd hits PFS in myeloma #mmsm #hematology
🔵 Fast track for VIR-5500 in mCRPC #pcsm
🩸 Epcoritamab+R-CHOP hits PFS in DLBCL #lymsm

www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 10/4/2026 | OncLive
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
www.onclive.com
October 11, 2026 at 12:27 PM
onclive.bsky.social
How are experts navigating subcutaneous therapy administrations in multiple myeloma? Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, break down newer patient-centric approaches #mmsm #oncology

Listen now: www.onclive.com/view/navigat...
Navigating Patient-Centric Treatment Administration Strategies in Myeloma | OncLive
Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discuss how on-body administration methods are affecting myeloma management.
www.onclive.com
October 9, 2026 at 7:27 PM
onclive.bsky.social
🗞️ Just in: The phase 3 EXCALIBER-RRMM trial met its second dual primary end point, with iberdomide plus daratumumab/dexamethasone extending PFS vs DVd in patients with R/R multiple myeloma #mmsm #oncology

Read more: www.onclive.com/view/iberdom...
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma | OncLive
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
www.onclive.com
October 8, 2026 at 3:40 PM
onclive.bsky.social
A real-world study from @moffittnews.bsky.social showed talquetamab produced similar response rates in patients with relapsed/refractory multiple myeloma, irrespective of whether they met the eligibility criteria for MonumenTAL-1 #mmsm #oncology

Read more: www.onclive.com/view/talquet...
Talquetamab Demonstrates Preserved Activity in MonumenTAL-1–Ineligible Patients With Relapsed/Refractory Myeloma | OncLive
Most patients treated with talquetamab at a single center would not have qualified for MonumenTAL-1, yet responses were similar regardless of trial eligibility.
www.onclive.com
October 6, 2026 at 1:42 PM
onclive.bsky.social
👀 NXC-201, a sterically optimized BCMA-directed CAR T-cell therapy, produced a high response rates in R/R AL amyloidosis, according to an interim update from the phase 1b/2 NEXICART-2 trial.

Full details 📰: www.onclive.com/view/nxc-201...

#oncology #mmsm
NXC-201 Elicits High Complete Response Rate in R/R AL Amyloidosis | OncLive
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
www.onclive.com
October 1, 2026 at 2:47 PM
imfmyeloma.bsky.social
We're LIVE today at 7pm ET with myeloma specialist Dr. Douglas Sborov! Get ready to ask him all your myeloma questions as we close out #BloodCancerAwarenessMonth. Click "Going" on Facebook & turn on notifications to RSVP: https://www.facebook.com/events/1388778123259596/

#KnowMyeloma #mmsm
September 29, 2026 at 2:53 PM
eshaematology.bsky.social
📣 ESHLYMPHOMA2026 PROGRAMME HIGHLIGHT:
SESSION 6 "Hodgkin lymphoma"
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #Haematology #MMsm #Lmsm
September 29, 2026 at 8:52 AM
ashclinicalnews.bsky.social
In treating R/R #MMsm, BCMA-targeted CAR-T therapy prior to a bispecific antibody led to greater OS rates (79% vs. 63%) than did a bispecific antibody followed by CAR-T therapy, suggesting that such a sequencing strategy could improve survival probability: https://ow.ly/Q2X450ZRwY3
September 25, 2026 at 5:00 PM
imfmyeloma.bsky.social
How can older myeloma patients decide what treatment is still worth pursuing? IMF NLB member Sam Shenoy answers and points to the IMF's free Decision-Making Tool at myeloma.org.

#AsktheIMF #KnowMyeloma #mmsm
September 22, 2026 at 8:03 PM
onclive.bsky.social
The EMA's CHMP offered a positive opinion recommending the approval of teclistamab for the treatment of adult patients with R/R multiple myeloma who have received at least 1 prior therapy #mmsm #oncology

Read more: www.onclive.com/view/chmp-re...
September 18, 2026 at 4:11 PM